Cerivastatin and Reports of Fatal Rhabdomyolysis
Top Cited Papers
- 14 February 2002
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 346 (7) , 539-540
- https://doi.org/10.1056/nejm200202143460721
Abstract
Bayer's voluntary withdrawal of cerivastatin from the U.S. market led to questions regarding the safety of all hydroxymethylglutaryl–coenzyme A reductase inhibitors, or statins. Myopathy and the rarer severe rhabdomyolysis are considered adverse events of therapy with this class of drugs.1 Concomitant use of drugs that can increase blood levels of statins can increase the risk of myopathy, as can concomitant use of gemfibrozil.2 We summarize the U.S. reports of fatal rhabdomyolysis associated with all six drugs in this class: lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin, and cerivastatin.Keywords
This publication has 2 references indexed in Scilit:
- Spontaneous Reporting in the United StatesPublished by Wiley ,2000
- Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapyJAMA, 1990